Pyxis Oncology Inc. (PYXS)
NASDAQ: PYXSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PYXS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $216.49M
- EPS (TTM)
- -$1.27
- Dividend yield
- None
- 52-week range
- 1.03 – 5.55
- Day range
- 1.70 – 1.99
- Volume / Avg
- 3.05M / 1.06M
- Beta
- —
- Shares outstanding
- 119.61M
52-week range
PYXS stock today
On Nov 20, PYXS ended the session at $1.81, adding $0.13 (7.74%), versus the S&P 500's 3.70% decline. Volume was 2.9x the average at 3.05M shares, a sign of unusually heavy trading. At this level, PYXS sits near the bottom of its 52-week range of $1.03 to $5.55: 67.4% below the high, set on Nov 26, 2025 and 75.7% above the low.
PYXS is up 57.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.3%. Pyxis Oncology has posted a net loss over the last twelve months (EPS of -$1.27), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Pyxis Oncology
Company profilePyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Thomas Civik
- Headquarters
- Boston, MA
- Employees
- 56
- IPO year
- 2021
- Website
- pyxisoncology.com
Financial highlights
Full financialsIn fiscal 2025, Pyxis Oncology generated $13.9 million in revenue, down 14.2% from fiscal 2024, the first decline in the 6 years shown. Pyxis Oncology reported a net loss of $79.6 million, compared with a loss of $77.3 million a year earlier. Gross margin was 82.8% (down from 97.1%) and operating margin -609.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $13.86M | $16.15M | — | — | — |
| Growth | -14.17% | — | — | — | — |
| Net income | $-79.62M | $-77.33M | $-73.79M | $-120.72M | $-75.97M |
| EPS (diluted) | $-1.28 | $-1.32 | $-1.85 | $-3.65 | $-8.95 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$8.22+354.14%
- Strong buy 1
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.24 vs $-0.27
- Surprise
- +11.11%
PYXS news
All PYXS news- Pyxis Oncology Announces Updated MICVO Phase 1 Monotherapy Data in 2L+ R/M HNSCCNasdaqPYXS, HEI.A
- Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR SymposiumGlobeNewswire
- Pyxis Oncology to Participate in Upcoming Investor ConferencesGlobeNewswire
- Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsGlobeNewswire
Pyxis Oncology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KROSKeros Therapeutics Inc. | 11.08 | -2.72% | $217.44M | vs PYXS |
| RCKTRocket Pharmaceuticals Inc. | 1.95 | -7.58% | $217.74M | vs PYXS |
| ARCTArcturus Therapeutics Holdings Inc. | 7.45 | -1.97% | $214.73M | vs PYXS |
| IMRXImmuneering Corporation Class A | 3.38 | -2.03% | $218.90M | vs PYXS |
| ENTAEnanta Pharmaceuticals Inc. | 7.62 | -4.51% | $222.19M | vs PYXS |
| CYPHCypherpunk Technologies Inc. | 1.41 | -18.02% | $210.15M | vs PYXS |
| VNDAVanda Pharmaceuticals Inc. | 3.45 | -6.13% | $208.32M | vs PYXS |
| FTHFaeth Therapeutics Inc. | 7.88 | -9.32% | $203.65M | vs PYXS |
Indexes, lists and sector
Pyxis Oncology stock FAQ
What is Pyxis Oncology's stock price today?
PYXS last traded at $1.81 as of Nov 20, 4:00 PM EST, up 7.74% on the day. Prices are delayed at least 15 minutes.
Who is Pyxis Oncology's CEO?
Mr. Thomas Civik is the chief executive officer of Pyxis Oncology Inc., which has about 56 employees.
What is the PYXS 52-week high?
The 52-week high for PYXS is $5.55 and the 52-week low is $1.03. The stock is currently 67.4% below its high.